Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome- An Analysis of the TENOR Study

Jul 1, 2007, 00:00
10.1111/j.1524-4733.2007.00179.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60609-2/fulltext
Title : Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome- An Analysis of the TENOR Study
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60609-2&doi=10.1111/j.1524-4733.2007.00179.x
First page :
Section Title :
Open access? : No
Section Order : 3

Objective

Tegaserod is effective, safe, and well-tolerated in the treatment of patients with irritable bowel syndrome (IBS) with constipation. The aim of this study was to assess, from a payer perspective, the cost-effectiveness of tegaserod in the treatment of IBS patients, based on the TEgaserod in NORdic region (TENOR) trial data.

Methods

Female and male patients (Rome II criteria) were randomized to receive tegaserod 6 mg b.i.d. or placebo for 12 weeks. Patients (247 tegaserod; 238 placebo) completed the EuroQol EQ-5D questionnaire at baseline, Week 4, and Week 12. A 12-week economic study was undertaken to assess the incremental cost-effectiveness ratio (ICER) of tegaserod in terms of cost per quality-adjusted life-year (QALY) gained. Cost-effectiveness acceptability curves were calculated toestimate the probability of tegaserod being cost-effective at different benchmark values of cost per QALY gained.

Results

By assuming a daily drug cost to payers of 50,000 per QALY gained ranging between 90% and 69%.

Conclusion

This study established directly from a randomized controlled clinical trial that tegaserod is cost-effective in the treatment of non-D-IBS patients.

Categories :
  • Clinical Trials
  • Economic Evaluation
  • Gastrointestinal Disorders
  • Specific Diseases & Conditions
  • Study Approaches
  • Trial-Based Economic Evaluation
Tags :
  • clinical trial
  • constipation
  • irritable bowel syndrome
  • Nordic
  • quality of life
  • quality-adjusted life-years
  • tegaserod
  • therapeutic
Regions :
  • Western Europe
ViH Article Tags :